Related Experiment Video
Updated: May 21, 2026
07:41
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
SERPINE1 expression discriminates site-specific metastasis in human melanoma
Experimental Dermatology
|June 22, 2012
Summary
The serine protease inhibitor SERPINE1 is highly expressed in melanoma, particularly in cutaneous metastases. Its expression level may influence melanoma
Area of Science:
- Oncology
- Biochemistry
- Dermatology
Background:
- Depth of invasion is a key melanoma staging factor.
- Pericellular proteolysis, regulated by serine proteases and matrix metalloproteinases, facilitates stromal penetration.
- SERPINE1 (serine protease inhibitor 1) is implicated in tumor progression and is a poor prognosis biomarker.
Discussion:
- SERPINE1 expression was analyzed in human melanoma tissues (primary, metastatic, normal skin).
- In normal epidermis, SERPINE1 is restricted to the basal layer.
- Elevated SERPINE1 immunoreactivity was observed in 96% of primary and 92% of metastatic melanomas.
Key Insights:
- Cutaneous metastases showed significantly higher SERPINE1 levels (80%) compared to lymph node lesions.
- Moderate SERPINE1 expression was common in primary melanomas.
- Metastatic deposits exhibited variable SERPINE1 levels (reduced or increased), suggesting a role in site-specific dissemination.
Outlook:
- Cutaneous metastases may represent a distinct high-SERPINE1 tumor subtype.
- Further research into SERPINE1's role could identify new therapeutic targets for melanoma.
- Understanding SERPINE1 amplitude may refine prognostic models and predict metastatic potential.
